Drug intelligence / Profile preview

BioCreatrix personalized cancer vaccine

Development stage: Preclinical
Lead developer: BioCreatrix
Modality: Vaccines & Immunotherapeutics

Overview

BioCreatrix's personalized cancer vaccine is a therapeutic immunotherapy designed to treat tumors by targeting patient-specific neoantigens. The process involves identifying unique genetic mutations within an individual's tumor and creating a customized vaccine to stimulate the patient's immune system to recognize and attack these specific cancer cells. This personalized approach aims to provide a highly specific anti-tumor response with minimal off-target effects on healthy tissue. The program is currently in the IND-enabling stage of development.

Other names: Personalized cancer vaccineneoantigen-based vaccine

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on BioCreatrix personalized cancer vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCreatrix personalized cancer vaccine.

Explore the full profile